|
1
|
Hehlmann R, Hochhaus A and Baccarani M;
European LeukemiaNet, : Chronic myeloid leukaemia. Lancet.
370:342–350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Deininger MW, Shah NP, Altman JK, Berman
E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L,
et al: Chronic myeloid leukemia, version 2.2021, NCCN clinical
practice guidelines in oncology. J Natl Compr Canc Netw.
18:1385–1415. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Palumbo A and Anderson K: Multiple
myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey
DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN: Diagnosis and
management of multiple myeloma: A review. JAMA. 327:464–477. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maerki J, Katava G, Siegel D, Silberberg J
and Bhattacharyya PK: Unusual case of simultaneous presentation of
plasma cell myeloma, chronic myelogenous leukemia, and a jak2
positive myeloproliferative disorder. Case Rep Hematol.
2014:7384282014.PubMed/NCBI
|
|
6
|
Ali N, Pickens PV and Auerbach HE:
Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic
myelogenous leukemia in a single patient treated simultaneously
with lenalidomide, bortezomib, dexamethasone and imatinib. Hematol
Rep. 8:62952016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Michael M, Antoniades M, Lemesiou E,
Papaminas N and Melanthiou F: Development of multiple myeloma in a
patient with chronic myeloid leukemia while on treatment with
imatinib mesylate for 65 months. Oncologist. 14:1198–1200. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
MacSween JM and Langley GR: Light-chain
disease (hypogammaglobulinemia and Bence Jones proteinuria) and
sideroblastic anemia-preleukemic chronic granulocytic leukemia. Can
Med Assoc J. 106:995–998. 1972.PubMed/NCBI
|
|
9
|
Garipidou V, Vakalopoulou S and Tziomalos
K: Development of multiple myeloma in a patient with chronic
myeloid leukemia after treatment with imatinib mesylate.
Oncologist. 10:457–458. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Romanenko NA, Bessmel'tsev SS, Udal'eva
VIu, Zenina MN, Martynkevich IS, Rugal' VI and Abdulkadyrov KM: The
combination of chronic myeloid leukemia and multiple myeloma in one
patient. Vopr Onkol. 59:103–110. 2013.(In Russian). PubMed/NCBI
|
|
11
|
Offiah C, Quinn JP, Thornton P and Murphy
PT: Co-existing chronic myeloid leukaemia and multiple myeloma:
Rapid response to lenalidomide during imatinib treatment. Int J
Hematol. 95:451–452. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sokal JE, Cox EB, Baccarani M, Tura S,
Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F,
et al: Prognostic discrimination in ‘good-risk’ chronic
granulocytic leukemia. Blood. 63:789–799. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kumar S, Paiva B, Anderson KC, Durie B,
Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, et
al: International Myeloma Working Group consensus criteria for
response and minimal residual disease assessment in multiple
myeloma. Lancet Oncol. 17:e328–e346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised International staging system
for multiple myeloma: A report from International Myeloma Working
Group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ragupathi L, Najfeld V, Chari A, Petersen
B, Jagannath S and Mascarenhas J: A case report of chronic
myelogenous leukemia in a patient with multiple myeloma and a
review of the literature. Clin Lymphoma Myeloma Leuk. 13:175–179.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Melo JV, Hughes TP and Apperley JF:
Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program.
2003:132–152. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carulli G, Cannizzo E, Ottaviano V,
Cervetti G, Buda G, Galimberti S, Baratè C, Marini A and Petrini M:
Abnormal phenotype of bone marrow plasma cells in patients with
chronic myeloid leukemia undergoing therapy with Imatinib. Leuk
Res. 34:1336–1339. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Katzel JA, Lee-Ma A and Vesole DH: Safety
of a second-generation tyrosine kinase inhibitor and novel targeted
therapy for the treatment of a patient with chronic myeloid
leukemia and multiple myeloma. Anticancer Drugs. 26:907–909. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ide M, Kuwahara N, Matsuishi E, Kimura S
and Gondo H: Uncommon case of chronic myeloid leukemia with
multiple myeloma. Int J Hematol. 91:699–704. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Macauda A, Giaccherini M, Sainz J,
Gemignani F, Sgherza N, Sánchez-Maldonado JM, Gora-Tybor J,
Martinez-Lopez J, Carreño-Tarragona G, Jerez A, et al: Do
myeloproliferative neoplasms and multiple myeloma share the same
genetic susceptibility loci? Int J Cancer. 148:1616–1624. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Swaminathan N, Gupta S and Dourado C: Case
Report: IgG multiple myeloma and chronic myeloid leukemia in a
single patient. F1000Res. 9:4882020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hideshima T, Mitsiades C, Tonon G,
Richardson PG and Anderson KC: Understanding multiple myeloma
pathogenesis in the bone marrow to identify new therapeutic
targets. Nat Rev Cancer. 7:585–598. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Avet-Loiseau H, Attal M, Moreau P,
Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M,
Yakoub-Agha I, Garderet L, et al: Genetic abnormalities and
survival in multiple myeloma: The experience of the Intergroupe
Francophone du Myélome. Blood. 109:3489–3495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thomas A, Mailankody S, Korde N,
Kristinsson SY, Turesson I and Landgren O: Second malignancies
after multiple myeloma: From 1960s to 2010s. Blood. 119:2731–2737.
2012. View Article : Google Scholar : PubMed/NCBI
|
